Innovent and HutchMed Report Positive Results from Combo CRC Therapy
June 09, 2021 at 05:07 AM EDT
Suzhou Innovent Bio and HutchMed announced positive data from their combination therapy for colorectal cancer. The regimen combines Innovent's approved PD-1, Tyvyt® (sintilimab injection) with HutchMed's VEGFR inhibitor, Elunate® (fruquintinib), as a third-line therapy for CRC. In 44 previously treated CRC patients, the objective response rate was 22.7%, about double the ORR of Elunate alone. The Phase Ib trial tested safety and efficacy of the combination and determined the recommended Phase II dose. More details... Stock Symbols: (HK: 01801) (NSDQ/AIM: HCM) Share this with colleagues: // //